<DOC>
	<DOC>NCT01709461</DOC>
	<brief_summary>the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.</brief_summary>
	<brief_title>Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>subjects who are willing to contiue this treatment. subjects who took part in the TVP 1012/501 clinical trail. subjects who didn't take part in the TVP 1012/501 clinical trail.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>